HOW WE CAN HELP YOU
Our Services for Professional Investors:
- Biotech and Pharmaceutical Asset Ratings
- Strategic Portfolio Support
- Recommendation of Assets for Your Specific Needs
- Competitive Landscaping of Your Areas of Interest
- Second Investment Opinion and Due Diligence
ASSET RATINGS
Biotech Investments is a leader in pharmaceutical asset ratings. Our unique Asset Rating Simulator is an elegant tool to simulate the medical potential of drug candidates.
Our Asset Rating Reports describe the rating of a specific asset in full detail, including a critical appraisal on the MoA, preclinical and clinical data, trial design, and a competitor overview.
Get an Expert Opinion from our independent medical experts and discuss opportunities and risks of a specific asset in the context of the whole clinical pipeline.
LEARN MORE
ON-DEMAND ASSET RATINGS
Biotech Investments also offers On-Demand Asset Ratings for all therapeutic areas, including neurology, immunology, oncology, ophthalmology, rare disease, among many others.
Discover interesting new investment opportunities or use our analyses for due diligence or a second investment opinion. On-Demand Asset Rating Reports can be combined with an independent medical Expert Opinion.
GET EXPERT OPINION
BIOTECH AND PHARMA NEWS
April 25, 2024
Mainz BioMed N.V.
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
View Article
April 25, 2024
SynBiotic SE
1.6 million euros for Hanf Farm: Federal Ministry for Economic Affairs and Climate Protection funds bio-economy project (news with additional features)
View Article
April 25, 2024
Asklepios Kliniken
Asklepios Group: Asklepios shows resilience in 2023 financial year
View Article